The arrival of Floxin Otic will aid in the treatment of approximately five million people in the U.S. suffering from specific middle and outer ear infections. For these two groups, Floxin Otic stands alone as the first and only drug approved for their treatment. The drop may be used alone without oral antibiotic therapy. This may help to alleviate some parental concerns over the frequent use of oral antibiotics in their children. This infection generally occurs during the summer months.
Topical treatment is standard therapy for outer ear infections.
Floxin Otic is the first twice-daily topical therapy approved for the treatment of these infections and, with its near neutral pH level, it may minimise the patient's discomfort. It is the first new topical solution in 20 years approved by the FDA for treatment of outer ear infections. Floxin Otic is contraindicated in patients with a history of hypersensitivity to ofloxacin, other quinolones, or other ingredients of the medication, and should be discontinued at the first sign of allergic reaction. Patients who have not improved after one week of treatment should be evaluated by their doctor. Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.